> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Syndax CEO: 40% Of NPM1 Leukemia Patients On Revuforj Reach Transplant, 'A Lot Higher Than We Had Expected'
- URL: https://www.bullished.co/syndax-ceo-40-of-npm1-leukemia-patients-on-revuforj-reach-transplant-a-lot-higher-than-we-f6b203d2/
- Published: 2026-11-02T23:05:56.000Z
- Updated: 2026-11-06T09:05:26.000Z
- Description: Management says transplant patients pausing then resuming Revuforj will lift revenue most in 2027, as third-quarter revenue hit $83.3 million.
- Author: Matteo Parrino
- Tags: Earnings, SNDX, Industry: Healthcare

About 40% of NPM1 leukemia patients on Revuforj now go to transplant, Syndax Chief Executive Officer Michael Metzger said on the company's earnings call Monday, a rate he called "a lot higher than we had expected." The company reported [$83.3 million in third-quarter revenue](https://www.globenewswire.com/news-release/2026/11/02/3393699/0/en/syndax-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co), up 82% from a year earlier.

## A transplant rate that surprised management

[Syndax](https://www.bullished.co/tag/sndx/), a commercial-stage cancer drugmaker that sells Revuforj and, with partner Incyte, Niktimvo, said about 50% of NPM1 patients who transplant resume therapy. Metzger said he expects perhaps 60% to 70% of them eventually to do so, calling that more projection than hard rule, based on physician conversations and the company's research.

Chief Commercial Officer Steve Closter said clinical trials showed about 11% of NPM1 patients going to transplant. He said the effect "may not be just a Menin effect" but "a Revuforge effect," and that about 75% of use is in first and second line, with combination treatment in about 40% of patients.

Asked by a Stifel analyst whether 40% is durable or an artifact of newly onboarded patients, Metzger pointed to earlier treatment, combination use and better transplant techniques that physicians have described.

## Why 2027 carries the payoff

Patients typically transplant within about three months of starting Revuforj, then pause for perhaps two to four or five months before resuming, Metzger said. That delays the revenue lift until returning patients outnumber those who dropped off. "2027 is where you'll see the greatest impact," he said.

For KMT2A patients, Metzger said the transplant rate is about 50% and the share resuming maintenance is 60%. Closter said management expects up to 70% to 80% of KMT2A patients eventually to return to therapy for one to two years. Metzger said NPM1 following the same pattern was "a bit of a news to us."

Revuforj net revenue was $61 million in the quarter. Closter estimated NPM1 accounted for more than 35% of it, and that about 50% of roughly 300 new patients were NPM1.

## A new CFO on November 9

Syndax also said CFO Keith Goldan is retiring, with Aaron Ondrey [taking over](https://www.globenewswire.com/news-release/2026/11/02/3393696/0/en/syndax-announces-cfo-transition-aaron-a-ondrey-appointed-chief-financial-officer.html?ref=bullished.co) effective Monday, November 9\. Goldan told a Mizuho analyst the decision was personal and not a loose use of the word retirement.

Goldan said the company ended the quarter with $551 million in cash, equivalents and investments, and that 2026 research and administrative spending guidance stays at about $400 million, excluding $50 million of estimated non-cash stock compensation.

New Revuforj data at the American Society of Hematology meeting in December will include frontline combination results and the first post-transplant maintenance data.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Syndax Pharmaceuticals GAAP EPS of -$0.55 misses by $0.04, revenue of $83.3M beats by $1.49M (SNDX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4662884-syndax-pharmaceuticals-gaap-eps-of-0%5F55-misses-by-0%5F04-revenue-of-83%5F3m-beats-by-1%5F49m?ref=bullished.co) — seekingalpha.com
- [Syndax names Aaron Ondrey CFO as Keith Goldan retires (SNDX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4662903-syndax-names-aaron-ondrey-cfo-as-keith-goldan-retires?ref=bullished.co) — seekingalpha.com
- [Syndax Reports Third Quarter 2026 Financial Results and](https://www.globenewswire.com/news-release/2026/11/02/3393699/0/en/syndax-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com
- [Syndax Announces CFO Transition – Aaron A. Ondrey Appointed](https://www.globenewswire.com/news-release/2026/11/02/3393696/0/en/syndax-announces-cfo-transition-aaron-a-ondrey-appointed-chief-financial-officer.html?ref=bullished.co) — globenewswire.com
- [Syndax Announces Participation in November Investor](https://www.globenewswire.com/news-release/2026/10/30/3392139/0/en/syndax-announces-participation-in-november-investor-conferences.html?ref=bullished.co) — globenewswire.com

### More on Syndax Pharmaceuticals

- [Syndax Revuforj Sales Climb 90% To $60.7 Million As Leukemia Drugmaker Swaps CFOs](https://www.bullished.co/syndax-revuforj-sales-climb-90-to-60-7-million-as-leukemia-drugmaker-swaps-cfos-7c980551/)
- [Syndax Revenue Jumps 82% To $83.3 Million, Yet Stockholders' Equity Slips Into A $17.2 Million Deficit](https://www.bullished.co/syndax-revenue-jumps-82-to-83-3-million-yet-stockholders-equity-slips-into-a-17-2-million-afdb1120/)

[All Syndax Pharmaceuticals (SNDX) coverage →](https://www.bullished.co/tag/sndx/)